Sarepta Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Sarepta Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2016 to Q3 2024.
  • Sarepta Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $395K, a 94.9% decline year-over-year.
  • Sarepta Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $7.56M, a 74% decline year-over-year.
  • Sarepta Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $15.9M, a 17.4% increase from 2022.
  • Sarepta Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $13.5M.
  • Sarepta Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was -$168K, a 116% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $7.56M $395K -$7.37M -94.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $14.9M $7.12M -$2.24M -23.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $17.2M $5.33M +$1.28M +31.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 $15.9M -$5.28M -$13.2M -167% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $29.1M $7.76M +$6.44M +488% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $22.7M $9.36M +$5.97M +176% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $16.7M $4.05M +$3.17M +360% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 $13.5M $7.94M +$7.85M +8528% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $5.68M $1.32M +$1.08M +457% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 $4.6M $3.39M +$3.74M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $854K $879K +$1.02M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 -$168K $92K -$740K -88.9% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $572K $237K +$141K +147% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $431K -$354K -$374K -1870% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 $805K -$143K -$258K -224% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $1.06M $832K +$121K +17% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 $942K $96K -$130K -57.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $1.07M $20K -$154K -88.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $1.23M $115K +$31K +36.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $1.2M $711K +$1.49M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$295K $226K +$900K Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$1.2M $174K -$448K -72% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$747K $84K -$55K -39.6% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$692K -$779K +$1.06M +57.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 -$1.76M -$674K -$2.69M -134% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 $930K $622K +$731K Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 $199K $139K -$1.86M -93.1% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 $2.06M -$1.84M Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 $2.01M +$2.01M Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$109K -$109K Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 $2M +$2M Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q3 2016 $0 Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-01
Q2 2016 $0 Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $0 Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.